Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer

BJU Int. 2007 Jul:100 Suppl 1:1-5. doi: 10.1111/j.1464-410X.2007.06967.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / pharmacokinetics
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Consensus
  • Delayed-Action Preparations
  • Humans
  • Leuprolide / pharmacokinetics
  • Leuprolide / therapeutic use*
  • Luteinizing Hormone / agonists*
  • Male
  • Professional Practice
  • Prostate-Specific Antigen / metabolism
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Testosterone / metabolism

Substances

  • Antineoplastic Agents, Hormonal
  • Delayed-Action Preparations
  • luprolide acetate gel depot
  • Testosterone
  • Luteinizing Hormone
  • Prostate-Specific Antigen
  • Leuprolide